How much can investors make with Bristol-Myers Squibb Company (BMY) stock in the next 12 months?

A share price of Bristol-Myers Squibb Company [BMY] is currently trading at $64.56, down -1.39%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BMY shares have lost -1.74% over the last week, with a monthly amount drifted -5.09%, and not seem to be holding up well over a long-time horizon.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


On 25, May 2023, Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023. In a post published today on Yahoo Finance, TRANSCEND CLL 004 is the first pivotal multicenter trial to evaluate a CAR T cell therapy in heavily pre-treated patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

From an analyst’s perspective:

Bristol-Myers Squibb Company experienced fluctuations in its stock price throughout the past year between $65.14 and $81.43. Currently, Wall Street analysts expect the stock to reach $79.79 within the next 12 months. Bristol-Myers Squibb Company [NYSE: BMY] shares were valued at $64.56 at the most recent close of the market. An investor can expect a potential return of 23.59% based on the average BMY price forecast.

Analyzing the BMY fundamentals

During the last quarter, Bristol-Myers Squibb Company [NYSE:BMY] saw sales of 11.34 billion, an decline of -2.70%. In the same period, the company’s revenue per employee was $1,345,743, whereas its income per employee was $184,461. Gross Margin for this corporation currently stands at +57.39% with Operating Margin at +20.08%, Pretax Margin comes in at +16.71%, and Net Margin reading is +13.71%. To continue investigating profitability, this company’s Return on Assets is posted at 6.14, Equity is 18.88, Total Capital is 12.08, and Invested Capital is 8.80. An extended look at the Principal structure reveals enduring liabilities to the total capital of 56.73 and enduring liabilities to assets of 42.05.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.98 points at the first support level, and at 63.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.15, and for the 2nd resistance point, it is at 65.73.

Bristol-Myers Squibb Company [BMY] reported earnings per share of $2.05 for its fiscal quarter that ended on 3/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.97/share, meaning a difference of $0.08 and a surprise factor of 4.10%. By comparison, the stated earnings for the previous quarter ended on 12/30/2022 were $1.82 per share as compared to estimates of $1.72 per share, a difference of $0.1 representing a surprise of 5.80%.

Ratios To Look Out For

A current ratio of 1.40 is a noteworthy aspect of Bristol-Myers Squibb Company [NYSE:BMY]. Further, the Quick Ratio stands at 1.14, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 3.35, the price to book ratio is 4.86 and the P/E (TTM) ratio is 18.81.

Transactions by insiders

Insider trading, which has resulted in 82 insider purchases of 695,729 shares and 45 insider sales of 398,221 shares in the past three months, is now the topic of our analysis. Recent insider trading involved VESSEY RUPERT, EVP & President, Research, that happened on May 03 when 50385.0 shares were sold. Board Chair and CEO, Caforio Giovanni completed a deal on Feb 06 to sell 0.24 million shares. Meanwhile, EVP, Chief Human Resources Powell Ann sold 11183.0 shares on Feb 06.